Tenon Medical (NASDAQ:TNON) Releases Quarterly Earnings Results

Tenon Medical (NASDAQ:TNON) released its quarterly earnings results on Thursday. The company reported ($5.39) earnings per share for the quarter, missing the consensus estimate of ($4.22) by ($1.17), FiscalAI reports. The business had revenue of $1.43 million during the quarter, compared to analysts’ expectations of $1.55 million. Tenon Medical had a negative net margin of 257.85% and a negative return on equity of 907.60%.

Here are the key takeaways from Tenon Medical’s conference call:

• Revenue and gross margin grew: Third-quarter revenue increased 22% year over year to $1.4 million, while gross margin rose to 66.3%. The company said operating expenses fell year over year and its operating loss improved to $3.1 million.
• Net loss widened: Third-quarter net loss was $6.6 million, compared with $3.3 million a year earlier, primarily due to non-cash warrant inducement expense and convertible-note interest expense.
• Debt repaid and capital raised: Tenon raised approximately $15.6 million in gross proceeds during the quarter and repaid its convertible notes in full, leaving no debt at quarter-end. It also reported about $7.1 million of availability under its ATM program.
• Commercial and product expansion underway: The company appointed a new chief revenue officer and fully launched its 3D-printed SImmetry+ lateral screw, which generated about $1.2 million during its limited launch. It is targeting a first-quarter 2027 market release for Quickstep and expects to submit an additional SImmetry+ enhancement in early December.

Tenon Medical Trading Down 8.7%

TNON opened at $1.63 on Friday. The stock has a market capitalization of $4.40 million, a P/E ratio of -0.04 and a beta of 1.43. The stock has a 50-day moving average price of $3.04 and a 200-day moving average price of $15.72. Tenon Medical has a 12-month low of $1.57 and a 12-month high of $43.05.

Insiders Place Their Bets

In other Tenon Medical news, major shareholder Financial Lp Hrt sold 65,582 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $5.56, for a total value of $364,635.92. Following the completion of the sale, the insider owned 15,839 shares of the company’s stock, valued at $88,064.84. This represents a 80.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders purchased 129,945 shares of company stock valued at $500,468 and sold 136,599 shares valued at $605,467. 17.71% of the stock is owned by insiders.

Analysts Set New Price Targets

TNON has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Tenon Medical in a report on Thursday, October 15th. Wall Street Zen downgraded shares of Tenon Medical from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Tenon Medical Company Profile

Tenon Medical, Inc. (NASDAQ:TNON) is a medical device company focused on developing and commercializing technologies for the treatment of sacroiliac (SI) joint dysfunction. The SI joint connects the lower spine to the pelvis and can be a source of chronic lower-back and pelvic pain. The company’s primary product is the Catamaran SIJ Fusion System, a minimally invasive surgical system designed to stabilize and fuse the SI joint through a transfixation approach. The system uses a specialized implant and delivery instruments intended to support placement across the SI joint while addressing the underlying source of instability.